🔴 Telix Pharmaceuticals is trading 4.29% down in pre-market as Q3 group revenue edged down 1% sequentially

Telix Pharmaceuticals is trading at $9.60, down 4.29%, as Q3 group revenue slipped 1% sequentially, a decline that appears to have disappointed investors.

• Q3 group revenue was US$245 million, up 19% year over year.
• Precision Medicine revenue was US$201 million, essentially flat from Q2; Telix reaffirmed full-year revenue guidance and said it was tracking toward the upper end.
• Shares fell 10.13% on October 21 after the update; weaker pre-market markets add risk-off pressure.